Vanda Pharmaceuticals, Inc.; Grant of Hearing Request Regarding a Proposal To Refuse To Approve a Supplemental New Drug Application for HETLIOZ (Tasimelteon)
NonrulemakingNoticeFDA-2022-N-2390-0669
Document
Details
The document's own metadata, straight from regulations.gov.
- Posted
- Jun 3, 2026
- Agency
- Food and Drug Administration (FDA)